(NASDAQ:FANG), MIDLAND, Texas, May 05, 2025 (GLOBE NEWSWIRE) — Diamondback Stockholders, This letter is meant to be a supplement to our earnings release and is being furnished to the Securities and Exchange Commission (SEC) and released to our stockholders simultaneously with our earnings release. Please see the information regarding forward-looking statements and non-GAAP financial information […]
(NasdaqGM:XENE), VANCOUVER, British Columbia and BOSTON, May 05, 2025 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its first quarter 2025 financial results and provide a business update after the close of U.S. financial
(NASDAQ:SNDX), – $20.0 million in Revuforj(R) (revumenib) net revenue in first full quarter of launch – – $13.6 million in Niktimvo(TM) (axatilimab-csfr) net revenue (reported by Incyte) in first partial quarter of launch – – Submitted sNDA for revumenib in R/R mNPM1 AML – – Initiated a pivotal frontline trial of revumenib plus ven/aza in
(NASDAQ:SLSN), First quarter revenue increased 48% to a record $14.6 million ROMEOVILLE, Ill., May 05, 2025 (GLOBE NEWSWIRE) — Solesence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the first quarter ended March 31, 2025. Recent Highlights and Accomplishments Uplisted to Nasdaq
(NASDAQ:MYRG), THORNTON, Colo., May 05, 2025 (GLOBE NEWSWIRE) — MYR Group Inc. (“MYR Group”) (NASDAQ: MYRG), a holding company of leading specialty contractors serving the electric utility infrastructure, commercial and industrial construction markets in the United States and Canada, announced it will attend the Stifel 2025 Boston Cross Sector 1×1 investor conference. MYR Group's Chief
(NasdaqGM:CHRS), REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2025 financial results will be released after market close on Monday, May 12, 2025. Starting at 5:00 p.m. EDT on May 12, 2025, Coherus' management team will host a conference call and webcast
(NASDAQ:CLDX), HAMPTON, N.J., May 05, 2025 (GLOBE NEWSWIRE) — Celldex announced today the presentation of histology data from the Company's ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE). Biopsies taken during screening demonstrate the presence of high numbers of intraepithelial mast cells in participants with active EoE and correlate with eosinophil counts, supporting
(NASDAQ:DORM), Highlights (All comparisons are to the prior year period unless otherwise noted): Net sales of $507.7 million for the quarter, up 8.3% compared to $468.7 million Diluted earnings per share (“EPS”) of $1.87, up 78% compared to $1.05 Adjusted diluted EPS* of $2.02, up 54% compared to $1.31 Generated $51 million of cash from
(NASDAQ:EDIT), CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q1 2025 financial results and business updates on May 12 via press release and SEC filings. As previously announced, the Company
(NasdaqGM:SOUN), SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of SoundHound AI, Inc. (NASDAQ: SOUN) securities between May 10, 2024 and March 3, 2025, both dates inclusive (the “Class Period”), have until Tuesday, May 27, 2025 to seek appointment as lead plaintiff of the